Red blood cells are effective carriers of anticancer drugs, as demonstrated by recent scientific studies.
NOT BSTOTAL BS
HARDLY BS — Verdict: Mostly True
Verified by Lenz ·
The Short Version
Recent studies do support red-blood-cell-based systems as promising anticancer drug carriers. Multiple peer-reviewed papers show improved delivery and, in some animal tumor models, better efficacy or lower toxicity. The key caveat is that most of this evidence is preclinical, so the claim should not be read as proof of established effectiveness in human cancer care.
Caveats
Most supporting evidence comes from animal and laboratory studies, not large human clinical trials.
The term covers different technologies—drug-loaded RBCs, RBC hitchhiking, and RBC-membrane-coated nanoparticles—which do not all have the same level of evidence.
Clinical translation remains limited by manufacturing, safety, and regulatory challenges.